{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:38:36Z","timestamp":1792643916788,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Temocillin, active against most extended-spectrum \u03b2-lactamases (ESBL)-producing\n                      <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic>\n                      , is increasingly considered a carbapenem-sparing option for Gram-negative infections. Despite a recommended pediatric dose of 25\u201350\u2009mg\/kg\/d in 2 administrations, its pharmacokinetics in children remain ill characterized. This study aimed to characterize temocillin pharmacokinetics in young children with urinary tract infections using population pharmacokinetic modeling and to evaluate target attainment using Monte Carlo simulations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Eligible patients contributed 1\u20132 blood samples collected at different time points, providing coverage of the dosing interval through an ethically acceptable sparse sampling strategy. Total and unbound temocillin plasma concentrations were quantified using high-performance liquid chromatography\u2013tandem mass spectrometry, and data were used for pharmacokinetic modeling. Probabilities of target attainment were calculated using Monte Carlo simulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Pediatric patients (6\u201334 months) hospitalized with urinary tract infection received temocillin at a dose of 25\u2009mg\/kg twice daily. Thirty unbound and 33 total plasma concentrations collected from 30 patients were available for analysis. A 1-compartment structural model including nonlinear protein binding was supported. Population pharmacokinetic estimates fell within the corresponding 95% confidence intervals and were consistent with bootstrap medians, supporting model stability. Clearance and volume of distribution were estimated at 2.81\u2009L\/h and 10.3\u2009L, respectively. Interindividual variability of clearance was determined to be 21.2% in the population. Modeling predicted that the studied regimen would provide a &gt;90% probability of target attainment against organisms with minimum inhibitory concentration (MIC) \u22642 mg\/L when targeting 40% of the dosing interval with free-drug concentrations above the MIC (40% fT&gt;MIC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Although sparse sampling limits parameter precision, characterization of interindividual variability, and covariate evaluation, these data may serve as an exploratory reference to inform preliminary dosing considerations in this pediatric population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005458","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:00:24Z","timestamp":1792641624000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic Modeling and Dosing Simulations of Temocillin in Children With Urinary Tract Infections"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6210-8100","authenticated-orcid":false,"given":"Xin","family":"Liu","sequence":"first","affiliation":[{"name":"Faculty of Health Medicine and Behavioural Science, University of Queensland Centre for Clinical Research, Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9713-3069","authenticated-orcid":false,"given":"Perrin","family":"Ngougni Pokem","sequence":"additional","affiliation":[{"name":"Pharmacologie Cellulaire et Mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 Catholique de Louvain (UCLouvain), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-3078","authenticated-orcid":false,"given":"Marc","family":"Hainaut","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Centre Hospitalier Universitaire de Bruxelles Saint-Pierre, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5863-6785","authenticated-orcid":false,"given":"Christine","family":"Ferreiro","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Centre Hospitalier Universitaire de Bruxelles Saint-Pierre, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Adler","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Centre Hospitalier Universitaire de Bruxelles Saint-Pierre, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Faculty of Health Medicine and Behavioural Science, University of Queensland Centre for Clinical Research, Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia"},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Queensland, Australia"},{"name":"Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women\u2019s Hospital, Brisbane, Queensland, Australia"},{"name":"Division of Anesthesia Critical Care and Emergency and Pain Medicine, Nimes University Hospital, University of Montpellier, Nimes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-7991","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Van Bambeke","sequence":"additional","affiliation":[{"name":"Pharmacologie Cellulaire et Mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 Catholique de Louvain (UCLouvain), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"R1-20261022","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1128\/AAC.22.3.453","article-title":"Antibacterial activity and beta-lactamase stability of temocillin.","volume":"22","author":"Jules","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"R2-20261022","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.20.1.38","article-title":"BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.","volume":"20","author":"Slocombe","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-20261022","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3390\/antibiotics14090859","article-title":"Temocillin: a narrative review of its clinical reappraisal.","volume":"14","author":"Cosimi","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"R5-20261022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dkn511","article-title":"Temocillin revived.","volume":"63","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R6-20261022","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkac286","article-title":"Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medications.","volume":"77","author":"Ngougni Pokem","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R7-20261022","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.cmi.2024.12.015","article-title":"Population pharmacokinetics and dosing simulations of temocillin in liver-transplanted paediatric patients: a prospective, open-label, non-randomized study.","volume":"31","author":"Ngougni Pokem","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"R8-20261022","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/jac\/dkae215","article-title":"Pharmacokinetics and pharmacological target attainment of standard temocillin dosing in non-critically ill patients with complicated urinary tract infections.","volume":"79","author":"Wijnant","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R10-20261022","first-page":"171","article-title":"Temocillin in the treatment of pyelonephritis in children.","volume":"13","author":"Verboven","year":"1987","journal-title":"Drugs Exp Clin Res"},{"key":"R11-20261022","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/jac\/dkae053","article-title":"Temocillin for febrile urinary tract infections caused by ESBL-producing Enterobacteriaceae in children: a monocentric exposed\/non-exposed study.","volume":"79","author":"Bayart","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R12-20261022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","article-title":"Human renal function maturation: a quantitative description using weight and postmenstrual age.","volume":"24","author":"Rhodin","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"R13-20261022","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clinbiochem.2015.02.006","article-title":"Validation of a HPLC-MS\/MS assay for the determination of total and unbound concentration of temocillin in human serum.","volume":"48","author":"Ngougni Pokem","year":"2015","journal-title":"Clin Biochem"},{"key":"R14-20261022","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD.","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R15-20261022","first-page":"695","article-title":"Pharmacokinetic studies in children: recommendations for practice and research.","volume":"103","author":"Barker","year":"2018","journal-title":"Arch Dis Child"},{"key":"R16-20261022","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/17425255.2024.2385403","article-title":"Dose optimization of beta-lactam antibiotics in children: from population pharmacokinetics to individualized therapy.","volume":"20","author":"Ngougni Pokem","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl 3","key":"R17-20261022","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1542\/peds.2008-1055f","article-title":"Behavioral approaches to anxiety and pain management for pediatric venous access.","volume":"122","author":"Cohen","year":"2008","journal-title":"Pediatrics"},{"key":"R18-20261022","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4155\/cli.14.97","article-title":"Blood volumes in pediatric clinical trials: a review of current regulations and guidance for research studies.","volume":"4","author":"Veal","year":"2014","journal-title":"Clin Invest"},{"key":"R21-20261022","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/jac\/dky078","article-title":"Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations.","volume":"73","author":"Miranda Bastos","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R22-20261022","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/antibiotics11070898","article-title":"Population pharmacokinetics of temocillin administered by continuous infusion in patients with septic shock associated with intra-abdominal infection and ascitic fluid effusion.","volume":"11","author":"Ngougni Pokem","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"R23-20261022","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.7326\/L21-0248","article-title":"Development and validation of a modified full age spectrum creatinine-based equation to estimate glomerular filtration rate.","volume":"174","author":"Pottel","year":"2021","journal-title":"Ann Intern Med"},{"key":"R24-20261022","doi-asserted-by":"crossref","first-page":"e0340649","DOI":"10.1371\/journal.pone.0340649","article-title":"Performance of glomerular filtration rate equations using serum creatinine in children with congenital anomalies of the kidney and urinary tract.","volume":"21","author":"Marpaung","year":"2026","journal-title":"PLoS One"},{"key":"R25-20261022","first-page":"262","article-title":"Developmental pharmacokinetics in pediatric populations.","volume":"19","author":"Lu","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R27-20261022","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/jac\/dku542","article-title":"Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.","volume":"70","author":"Soubirou","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 5","key":"R28-20261022","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003495-198500295-00020","article-title":"Pharmacokinetics of temocillin in volunteers.","volume":"29","author":"Hampel","year":"1985","journal-title":"Drugs"},{"key":"R29-20261022","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s10096-020-03844-5","article-title":"Activity of temocillin against ESBL-, AmpC-, and\/or KPC-producing Enterobacterales isolated in Poland.","volume":"39","author":"Kuch","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:00:29Z","timestamp":1792641629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005458","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"2026-05-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}